Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]

Trial Profile

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs Ularitide (Primary)
  • Indications Acute heart failure; Decompensated heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms TRUE-AHF
  • Sponsors Cardiorentis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Apr 2017 Primary endpoint (Cardiovascular death rate) has not been met, according to the results published in the New England Journal of Medicine.
    • 12 Apr 2017 Primary endpoint (Hierarchical clinical composite outcome 48 hr after randomization) has not been met, according to the results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top